Use of Contract Analytical Laboratories: A Pfizer Global Biologics Perspective - By following key strategies, companies can reduce the risk and increase the benefits of outsourcing analytical developm

ADVERTISEMENT

Use of Contract Analytical Laboratories: A Pfizer Global Biologics Perspective
By following key strategies, companies can reduce the risk and increase the benefits of outsourcing analytical development and testing


BioPharm International
Volume 22, Issue 7

Risk: The method transfer exercise does not adequately test the contract laboratory's capabilities.


Best Practices for a Successful Analytical Transfer to a Contract Analytical Laboratory
To truly have a successful analytical method transfer, the sponsor must have complete confidence in results generated by the contract analytical laboratory (see sidebar).

Recommendation: To accomplish this, we believe that a key factor is the design of the method transfer, or more specifically, the choice of the sample set to be used in the analytical method transfer exercise. Often, to save time or for the ease of the sponsor laboratory, analysts at the sponsor site and the contract analytical laboratory perform comparability testing on samples that have already been tested for release at the sponsor site. Although this is acceptable for part of the sample set, it is also important to use spiked or degraded samples in the comparability testing. By using samples that generate results that are out of the ordinary, the sponsor will better demonstrate that the contract analytical laboratory can obtain results equivalent to those obtained in the sponsor's own laboratories.

CONCLUSION

A key similarity among all of the recommendations given in the above examples is the necessity of constant communication. Communication is key to ensuring that analytical testing performed by a contract analytical laboratory is successful, from both a business and a scientific perspective. Current market trends in the pharmaceutical industry indicate that the use of contract analytical laboratories will only continue to grow, both domestically and internationally, in the coming years. Using the best practices and recommended strategies highlighted here can help sponsors to avoid pitfalls and mitigate the risks associated with the outsourcing of analytical testing.

John Ruesch is the associate director, and Amy St. Charles is a senior scientist, both in QC/Stability/Compliance in the Analytical Research and Development of Pfizer Global Biologics, St. Louis, MO, 636.247.5146,


blog comments powered by Disqus

ADVERTISEMENT

Moscow Hosts IFPMA Biosimilars Conference
May 17, 2013
AbbVie and Alvine Will Collaborate on Celiac Disease Therapy
May 15, 2013
FDA Issues Pharmacoepidemiologic Safety Study Guidance
May 14, 2013
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
May 13, 2013
Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International,
Click here